Edwards Lifesciences Boosts Growth Outlook on Strong TAVR and TMTT Sales — Edwards Lifesciences Corporation

Event summary

Q2 sales grew 13.6% to $1.74 billion, with constant currency growth at 12.5%.
TAVR sales increased 11.3% to $1.26 billion, driven by sustained clinical momentum.
TMTT sales surged 47.3% to $195.9 million, fueled by repair and replacement therapies.
Adjusted EPS of $0.78 beat expectations, supported by better-than-expected topline performance.

The big picture

Edwards Lifesciences is capitalizing on strong clinical evidence and regulatory tailwinds to drive growth across its structural heart portfolio. The company's strategic focus on innovation and global expansion positions it well in a competitive medical device market, with TAVR and TMTT therapies leading the charge. The upcoming regulatory decisions and clinical presentations will be key indicators of Edwards' ability to maintain its leadership position.

What we're watching

Regulatory Approvals: The anticipated Q4 approvals of PASCAL tricuspid indication in the U.S. and next-generation PASCAL with Capture Clarity in both the U.S. and Europe will be critical for TMTT growth.
Clinical Data Impact: The presentation of PROGRESS and CLASP IITR trial results at TCT could further solidify Edwards' leadership in structural heart therapies.
Market Expansion: Edwards' ability to sustain double-digit growth in both U.S. and international markets will depend on continued adoption of its SAPIEN platform and expansion into new centers.